

# PROF. PETRO TERBLANCHE

## Managing Director AFRIGEN BIOLOGICS



Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa's biotechnology strategy. She holds the position of Managing Director of Afrigen Biologics (Pty)Ltd based in Cape Town, South Africa. Afrigen hosts the global mRNA technology vaccine Hub under the COVAX initiative and has a mRNA Covid 19 vaccine candidate in development as part of a global program to build capacity and capabilities in LMICs to design, develop and produce mRNA vaccines. Petro also holds a part time position as Professor in the Faculty of Health Sciences at the North-West University. A considerable part of her career was in research, development and innovation at the South African Medical Research Council (SAMRC) as well as the Council for Scientific and Industrial Research (CSIR). She has held and holding several strategic public and private sector Board positions in SA as well as the position as President of the Stakeholders Organization for the Global Alliance for TB Drug Discovery and Development (2007-2010). She has several qualifications which include: a Master of Science and a Doctor of Science in Medical Oncology from the University of Pretoria, post-doctoral she was a visiting scientist at Harvard University School of Public Health and thereafter, completed a Management of Technology program at Massachusetts Institute of Technology in addition to several management and leadership programs from leading institutions globally. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.



# PROF. SARAH GILBERT

## Saïd Professor of Vaccinology PANDEMIC SCIENCES INSTITUTE



Sarah Gilbert received her undergraduate degree in Biological Sciences (specialising in Microbiology) from the University of East Anglia, and a PhD in Biochemistry from the University of Hull. She completed post-doctoral appointments at the Brewing Research Foundation and the University of Leicester before moving to Delta Biotechnology in 1989, working on the production of recombinant human blood proteins from yeast. She moved to Oxford University in 1994, as a senior post-doctoral researcher before being appointed University Research Lecturer (1999), Reader in Vaccinology (2004), Jenner Investigator (2006) and Professor of Vaccinology (2010). In 2021 Professor Gilbert was appointed to the Saïd Chair of Vaccinology and became Head of the Outbreak Pathogens Vaccine Group in the Pandemic Sciences Institute in the Nuffield Department of Medicine at Oxford University.

Professor Gilbert's research has been on the development of vaccines against infectious diseases, including vaccine design, preclinical and clinical assessment of vaccines produced using viral vector platform technologies. This has included the initial development of the novel simian adenoviral vectored vaccine technologies ChAdOx1 and ChAdOx2. Her research has included the development of Good Manufacturing Practice (GMP) manufacturing processes and assays to allow ChAdOx-vectored vaccines to be produced for clinical trials. In 2020 Professor Gilbert initiated and led the rapid production and development of a vaccine against SARS-CoV-2 (Vaxzevria) which was licensed to AstraZeneca and is now in use in over 180 countries.

Professor Gilbert was made a Dame Commander of the British Empire in 2021 in recognition of her work during the 2020 pandemic. Her book, *Vaxxers*, describing the development of Vaxzevria was a Sunday Times bestseller. Other awards include the Royal Society of Medicine Gold Medal, the Princesa de Asturias Award for Technical and Scientific Research, 2021 and the Sunhak Peace prize 2022.



# DR. STIG TOLLEFSEN

## Technology Office Lead CEPI



Immunologist with a PhD from the University of Oslo working with DNA vaccination with electroporation against *M. Tuberculosis* (2003). Started as post-doctor at Oslo University Hospital from 2002 working with focus on T cell responses in the autoimmune diseases type 1 diabetes and celiac disease, mapping gluten peptide binding to HLA DQ2 and DQ8 associated with the disease. From 2010 working at Norway Veterinary Institute with adaptive immunity in ruminants and working on vaccine development against *M. avium paratuberculosis*. Section head from 2013 at the NVI section for immunology. Started in Coalition for Epidemics Preparedness Innovations CEPI in 2019, being head of Strategic Science, coordinating CEPI Scientific Advisory Committee, and developing and launching the call for proposals for multipurpose vaccine technology platforms against infectious viral diseases with potential for epidemics. Since 2020 assigned to be the Technology office lead in CEPI. Main tasks were to be the gate keeper for the 5 rounds of COVID-19 vaccine development calls for proposals. In addition established the TechTalks in CEPI, as a meeting platform to discuss development and support for developers planning to apply to any of our calls, three years later we have had more than 300 TechTalks. Currently acting as Office of Technology Lead, to be an external research scout office. Current responsibility is looking for new technologies being developed in Europe and Australia that can help CEPI achieve the 100 days ambition for vaccine development.



# DR. FABRIZIO CHIODO

Assist. Professor  
ITALIAN NATIONAL  
RESEARCH COUNCIL  
FINLAY INSTITUTE  
CUBA



Fabrizio Chiodo studies adaptive and innate responses of non-mammalian glyco-conjugates, mostly in the context of vaccines and host-pathogen interactions. During his PhD (defended in 2013, San Sebastian, Spain), working on a new generation of vaccines technology he had a long stay at the Amsterdam Medical Center. In 2014 he started his independent research working at the Leiden Institute of Chemistry and Leiden University Medical Center. He initiated and strengthened International collaborations in the field of vaccinology especially with the Finlay Institute in Cuba, where he is an associate researcher and invited lecturer at the Faculty of Chemistry. In 2018 he moved to the Amsterdam Infection and Immunity Institute working independently as senior researcher. From October 2020 he is a research assistant professor at the Italian National Research Institute (CNR) working at the Institute of Biomolecular Chemistry, Naples, keeping his affiliation and position also in Amsterdam. He has been recently involved in the design and development of SARS-CoV-2 Soberana vaccines developed by Finlay Institute in Cuba.




# DR. JOSE CASTILLO

## CEO QUANTOOM BIOSCIENCES



As recognized technology leader in the biopharmaceutical industry, José brings a strong track record in innovative processes design and successful commercialization. Previous accomplishments include the start-up of Artelis, where he designed and developed bioreactors that transformed industrial operations – the iCellis system being now considered as standard in the vaccines and gene therapy industry. The technology was industrialized at ATMI LifeSciences and Pall Lifesciences, where José held the position of Cell Culture Technologies Director. Prior to Artelis, José was Head of Viral Vaccine Industrialization at GSK Vaccines. In 2013, José co-founded Univercells where he was the architect of highly efficient production processes that will make biologics available and affordable for all. The goal was to disrupt the industry and become the leader of comprehensive manufacturing solutions. In June 2021, José launched a new company, Quantoom Biosciences, with the mission to remove the barriers to making mRNA-based vaccines & therapeutics, at every stage from sequence up to mass production.

With a background in Chemical Engineering, Jose's education includes a PhD in Applied Sciences from the Université Libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.



# DR. AMADOU ALPHA SALL

## CEO INSTITUT PASTEUR DE DAKAR



Dr Amadou A Sall is a virologist and holds a doctorate in public health from Pierre et Marie Curie University in Paris (France). He did his graduate studies in life science at the universities of Paul Sabatier in Toulouse, Paris Orsay and Pierre and Marie Curie in France. His scientific training was acquired at the Institut Pasteur in Paris (advanced course in medical virology, doctoral thesis) but also through stays in several renowned scientific institutions such as the Institute of Virology and Microbiology of the environment of Oxford (United Kingdom), the Tropical Diseases Research Center of the Medical Branch of the University of Texas at Galveston (United States) or the Albert Einstein School of Medicine at Yeshiva University in New York. From 2002 to 2004, Dr Sall worked at the Institut Pasteur Cambodge to set up the laboratory on viral hepatitis. In 2010-2011, he worked as a visiting researcher at the Center for Infection and Immunity at the Mailman School of Public Health at Columbia University of New York on the discovery of new pathogens. Dr Sall has been Managing Director of the Institut Pasteur de Dakar (IPD) since September 1, 2016. In his 28-year career, he has been an intern, student, researcher, head of the molecular virology laboratory, head of the Arbovirus unit and Viral haemorrhagic fever and director of the WHO collaborating center, head of the virology pole and scientific director. Dr. Sall's research has mainly focused on the diagnosis, ecology and evolution of viral haemorrhagic fever arboviruses and viruses. He has published over 200 scientific articles in scientific journals including high impact (Nature, Lancet, Cell, Science, New England Journal of Medicine) or book chapters, a book on viral diagnostics and has given over 300 scientific communications at international meetings. He was awarded the Grand Prix of the President of the Republic of Senegal for the sciences (the highest scientific distinction in Senegal) in 2011 and the UNESCO Prize for the Life Sciences in 2015 for his research. He was admitted to the National Academy of Sciences and Techniques of Senegal in 2012. In public health, Dr Sall is an expert on epidemics and global health security. He was the



leader of the IPD team which deployed a mobile laboratory in Guinea in 2014-2016 to fight against the Ebola virus disease epidemic. He was the leader of the IPD team that was deployed to Sao Paulo, Brazil to Cuernavaca, Mexico and Cape Verde to fight the Zika virus outbreak at the request of these governments. He is a member of the 2 emergency committees of the International Health Regulations (for Zika and yellow fever) which advises the Director General of WHO on the advisability of declaring epidemics as public health emergencies of international concern. Since 2013, Dr Sall has been a member of the board of directors of the WHO Global Epidemic Alert and Response Network (GOARN) and chaired it from 2016 to 2018.

Since 2018, he has served on the technical committee and strategy (STAG) on infectious risks which advises the WHO deputy director general in charge of emergencies. He is a member of several WHO and OIE expert committees. In 2018, he was elevated to the rank of Knight of the National Order of the Lion of Senegal by the President of the Republic of Senegal for his action during the Ebola virus disease crisis in Senegal and West Africa. In 2021, the London School of Hygiene and Tropical Medicine awarded him its highest and most prestigious distinction the "Honorary Fellowship award" for "outstanding work" in global health. In 2021, he was elevated to the rank of Knight of the Legion d'honneur of France by the President of the Republic of France for his action during the COVID-19 crisis and the collaboration between France and Senegal in the domain of health. In the context of the COVID-19 crisis, Dr Sall is the co-chair of the laboratory technical group and a member of the board of directors of the African Union Task Force. In Senegal, he is a member of the Presidential Council's Commission for COVID-19. Dr Sall was auditioned as an expert on COVID-19 at the French National Assembly and the French Senate, the international association of French-speaking mayors, the ACT-A council and by the German parliament on vaccine equity. Dr Sall has been member of the commission of experts appointed by the President of the European Commission and Prime Minister Mario Draghi to make recommendations for the G20 summit in 2021. He was awarded as one of the 25 heroes of COVID-19 in April 2020 by Fortune magazine and the 100 most influential Africans by New Africa magazine. In education, Dr Sall founded an international course on "Diagnosis, Prevention, Control and Management of Outbreaks of Viral Hemorrhagic Fever". He has taught at Cheikh Anta Diop Dakar University, Columbia University in New York, Institut Pasteur in Paris, Institut Pasteur Montevideo, University of Sao Paulo, University of Hong Kong and the National Autonomous University of Mexico, the Institut Pasteur in Shanghai, McGill University in Canada and the Mérieux Foundation. Dr Sall sits on the scientific boards of FIND (Foundation for Innovative and New Diagnostics) in Geneva, the Medical Research Unit (MRC) of Gambia and served from 2016-2018 in that of CEPI (Coalition for Epidemics Preparedness and Innovation), from the Franco-Senegalese campus in Senegal. He sits on the boards of the African Society of Medical Laboratories (ASLM), the Canadian NGO GUARD (specializing in access to medical countermeasures for epidemics). Since 2017, Dr Sall has been a representative of the Pasteur Network in the Assembly of 100, one of the governing bodies of the Institut Pasteur in Paris. Since June 2021, Dr Sall is the president of the Pasteur Network, which has 32 institutes in 26 countries. Dr Sall is 53 years old and is married with 4 daughters.

# DR. JOE FITCHETT

## Senior Adviser INSTITUT PASTEUR DE DAKAR



Dr. Joe Fitchett is Senior Adviser for Biotechnology at the Institut Pasteur de Dakar, Senegal, and co-directs the Institute's Delivery Unit. In this role, he is responsible for the strategy to design, transfer, and scale production of medical countermeasures for epidemics as part of a newly established Dakar biotechnology hub. This includes the affordable measles/rubella vaccine program with Batavia Biosciences, Univercells and the Gates Foundation, as well as the 10-year IPD-CEPI partnership to establish a rapid response manufacturing facility for outbreak vaccines, launched in January 2023.

Dr. Fitchett joins the Institut Pasteur de Dakar from Global Access Diagnostics (GADx), an innovative life science and biotechnology company. Prior to GADx, Joe was a Program Officer at the Gates Foundation, responsible for advancing the foundation's bilateral partnerships with a number of EU donors, through joint investments and multilateral engagement.

Joe has trained in public health and infectious disease epidemiology (Harvard), clinical medicine (Imperial and Kings), and immunology of infectious diseases (LSHTM).





# DR. ANDREW FARLOW

Director of Global Health  
Policy Partnership  
NDM CENTRE FOR  
GLOBAL HEALTH  
RESEARCH



Andrew Farlow, a health economist educated at Cambridge and Oxford, leads development of the Global Health Policy Partnership, NDM Center for Global Health Research, currently focusing on AMR and antibiotics, future pandemic preparedness (including vaccines), AI for health and digital health, planetary health (including climate change, pollution, biodiversity and natural product medicines). His highly inter-disciplinary, policy-orientated approach is reflected in his positions – Senior Fellow at the Oxford Martin School, and, previously, Senior Research Fellow at the Department of Zoology (Spatial Ecology and Epidemiology Group), Senior Research Fellow at the Saïd Business School, and Department of Economics – and leadership of a series of cross-disciplinary vaccine projects. He lectures on Oxford’s International Health and Tropical Medicine on vaccine health economics, development, and deployment, and COVID-19 vaccine lessons and challenges. As a visiting professor at the Oswald Cruz Foundation, Brazil he has lectured on vaccines, technology, and policy, and is collaborating on natural product R&D and AI/digital health. Over more than 20 years he has provided advice to a wide range of public- and private-sector organizations, including: World Health Organization; UK Department of Health; Global Alliance for Vaccines and Immunization; UK Department for International Development; Bill and Melinda Gates Foundation; TB Alliance; Aeras Global TB Foundation; Pediatric Dengue Vaccine Initiative; US National Institutes for Health; Médecins Sans Frontières; Institute for Health Research, UK; South African Competition Commission; UK Treasury; Wellcome Trust; X Prize Foundation; Credit Suisse First Boston; Goldman Sachs; Dalberg Global Development Advisors; Oxford Analytica; Oxfam; ActionAid; and many others.



# DR. ELS TORREELE

Independent Consultant  
Visiting Fellow  
INSTITUTE FOR  
INNOVATION AND  
PUBLIC PURPOSE, UCL



Dr Els Torreele is a global health and innovation expert, focusing on transforming medical R&D to address priority health needs and ensure equitable access to knowledge and technologies. A Bio-Engineer and PhD from Brussels University, for over 20 years she has combined medical R&D work, policy research, and advocacy at Brussels University, Médecins Sans Frontières, Drugs for Neglected Diseases initiative, Open Society Foundations and is now independent consultant and Visiting Fellow at the Institute for Innovation and Public Purpose, University College London. A recent Rockefeller Bellagio Centre resident (March 2022), she's also an Honorary Science Fellow at the VUB, author on over 50 international journal publications, and regular contributor to the societal debate through media and social media (@ElsTorreele; @elstorreele@universeodon.com).

Working closely with former members of the Independent Panel for Pandemic Preparedness and Response, she's co-organizer of an upcoming Bellagio conference: "Advancing a new approach to pandemic tools as common goods" (13-17 February 2023) and lead author of its background paper "Stopping epidemics when and where they occur" (The Lancet, 12 Jan 2023)



# PROF. PIERO OLLIARO

Director of Science ISARIC  
Professor of Infectious  
Diseases of Poverty  
PANDEMIC SCIENCES  
INSTITUTE



Prof Piero Olliario is MD with post-graduation in infectious diseases (Pavia, IT), PhD (Pavia, IT), MA (Oxford, UK), HDR (Habilitation à Diriger les Recherches, Grenoble, FR). He is Membre Etranger de l'Académie de Médecine (French Academy of Medicine) and was Newton-Abraham professor 2014-15 with Lincoln college, University of Oxford. He has dual nationality – Italy and Switzerland.

He is full professor and chair of Infectious Diseases of Poverty at the University of Oxford, UK and Director of Science of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, Oxford, UK. His current primary area of work is epidemic preparedness and response – including clinical research in covid-19, plague, Lassa fever, monkeypox, and other high-consequence infectious diseases. Other research subjects covered throughout his career are diagnosis, treatment, and prevention of neglected tropical diseases (primarily: leishmaniasis, schistosomiasis, soil-transmitted helminths, dengue), malaria, tuberculosis.

Previously, he worked for 25 years for the World Health Organization (WHO) and led Intervention and Implementation at the Special Programme on Research and Training in Tropical Diseases (TDR).

He is author of 426 peer-reviewed articles (January 2023) and numerous other documents and interventions in international congresses.

